Specialist experience and knowledge
Peter Fellner (67)
Dr Peter Fellner was appointed Chairman in May 2009, having served as a director since November 2005. He is also Chairman of Vernalis plc, Optos plc, Biotie Therapies Corp. and Astex Therapeutics Ltd. In addition he serves as a director of the global biopharmaceutical company UCB SA. He is a member of the Novo A/S Advisory Group. Dr Fellner previously served as Chairman of Celltech Group plc from 2003 to July 2004, having been CEO from 1990 onwards. Before joining Celltech he was CEO of Roche UK from 1986 to 1990. More recently he served as Chairman of Acambis plc from 2006 until its acquisition by Sanofi Aventis in 2008, and of Premier Research Group plc from 2007 to 2008, when it was acquired by a private-equity backed group.
Jonathan Glenn (42)
Jonathan Glenn was appointed Chief Executive in December 2007 and before that had been Group Finance Director since September 2006. Prior to joining Consort Medical plc, Jonathan was global Head of Finance at Celltech Group plc and later Chief Financial Officer of Akubio Ltd, a Cambridge-based developer of instrumentation for the life sciences industry. He is a member of the Institute of Chartered Accountants in England and Wales.
Toby Woolrych (44)
Group Finance Director
Toby Woolrych was appointed as Group Finance Director in October 2008. He was previously Chief Financial Officer and Chief Operating Officer at Acta SpA, a renewable energy company. Having qualified as a chartered accountant with Arthur Andersen in 1992 he became Finance Director of Medicom International Ltd, a medical publishing company. In 1997, he joined Johnson Matthey plc, initially as Corporate Development Manager and subsequently as Division Finance Director and then Managing Director of a global speciality chemicals business unit.
Nick Higgins (54)
Corporate Development Director
Nick Higgins was appointed Corporate Development Director on 1 January 2011, having joined the Company in January 2010. Nick has spent over 25 years in the healthcare industry focusing on business and corporate development. He joined the Company from Intercytex Group plc where he was Chief Executive for five years. Prior to that he was Chief Business Officer of Acambis plc, a vaccines specialist, for 11 years. Before Acambis he worked for Porton Developments, the PA Consulting Group and Unilever.
George Kennedy CBE (70)
George Kennedy was appointed as a non-executive director in September 2006. He is currently Deputy Chairman of Vernalis plc and Chairman of Eschmann Limited. A former Chairman of Smiths Industries Medical Group, George also served as Chairman of the UKTI Trade Advisory Group for Africa and the Middle East. He is an ex-Chair and current President of the Association of British Healthcare Industries. George was awarded the CBE in 1997 for services to the healthcare industry.
Chris Banks (61)
Chris Banks was appointed as a non-executive director in April 2006. He was Finance Director at The BIS Group from 1985 to 1991 and at CMG plc from 1992 to 2000. Until March 2011 he was Chairman of the Audit Committee and the senior independent director of The Innovation Group plc. He is currently Chairman of the Audit Committee and the senior independent director of Digital Barriers plc and a trustee of the Barbara Ward Children’s Foundation. He is a Chartered Accountant and a member of the Association of Corporate Treasurers.
Jim Dick (58)
Jim Dick was appointed as a non-executive director in April 2006, having served as President of Smith & Nephew plc’s Wound Management Division since 1999. He is Chairman of Cat. Zero, a charity aimed at changing the lives of young people who are not in education, employment or training. He is Pro-Chancellor and also a member of the Council of the University of Hull, a member of the Management Board of the Hull York Medical School and is Chair of the Yorkshire Health Innovation Network.
Dr William Jenkins (63)
Dr William Jenkins was appointed as a non-executive director in May 2009 and is Principal of William Jenkins Pharma Consulting. He has been advising a wide range of pharma and biotech companies and investment and venture capital firms in the healthcare sector since 1999. Formerly head of Worldwide Clinical and Regulatory Affairs for Novartis Pharma AG and held similar positions with Ciba Geigy AG and Glaxo. He is also a director of Vaximm AG.
Dr Lynn Drummond (51)
Dr Lynn Drummond was appointed as a non-executive director on 9 February 2011. Lynn is a Fellow of the Royal Society of Edinburgh and the Royal Society of Chemistry and is currently a non-executive director of Alimentary Health Limited, a biotechnology company specialising in commercialising probiotics for medical use, based in Cork, Ireland. She was previously a Managing Director at Rothschild and her focus was on advising clients within the healthcare sector.
The first lightweight, cost-effective video laryngoscope with a clinician-friendly design, disposable channeled and non-channeled blades and reusable, integrated OLED video display.
the design, development
and supply of innovative
devices for delivery of injectable drug products.